• Basic Membership Access to Journal, Shadow Stock portfolio & monthly updates for stock screens
  • A+ Investor Full access to AAII.com, Journal, and a power data suite for investment ideas
  • AAII Platinum Full access to all of AAII's model portfolios and premium services at a significant discount
  • Dividend Investing Newsletter and model portfolio that focuses on dividend growth
  • AAII Growth Investing Find secular growth stocks poised for outperformance regardless of macroeconomic conditions.
  • Retirement Investing Discover trusted strategies for every stage of retirement. Get actionable insights and resources for smart retirement planning.
  • Sentiment Investing A research-driven newsletter with 10+ signals decoding sentiment across retail and institutional behavior.
  • Stock Superstars Report Get stock ideas inspired by the market's leading professionals
  • VMQ Stocks For the value investor looking to harness academic research in an actively managed portfolio
  • Bits and Bips Newsletter delivering insights on linking traditional finance, macro trends and cryptocurrency opportunities to help investors build stronger, more diversified portfolios.
All premium products come with free basic membership.
Explore All Membership Options
Join Now

Stock Evaluator: ADMA Biologics, Inc. (ADMA)

ADMA Biologics, Inc. ADMA

$10.05 0.51 5.35%
August 19, 2026 4:00:00 PM EST November 10, 2021 Volume: 2,688,960
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Commentary & Analysis

Financial Summary

Share Statistics ADMA Industry
Median		 Percentile
(All Stocks)
Market Cap (Mil) $2,186.1 $286.3 55%
Shares Out (Mil) 230.3 54.2 79%
Institutional Ownership 97.7% 92.8% 75%
Float (Mil) 219.7 39.7 76%
Beta na 0.94 na
Avg Daily Volume (000s) 2,183 534 83%
Price Change
(52-week)		 (44.0%) 58.7% 17%
Growth ADMA Industry
Median		 Percentile
(All Stocks)
Sales (5yr) 64.6% 13.6% 97%
Net Income (5yr) 31.6% (10.1%) 86%
EPS (5yr) 21.8% 16.0% 71
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (17.1%) (15.6%) 41%
Estimates Qtrly Current
Fiscal
Year		 Next
Fiscal
Year
# of Estimates 3 3 4
Current EPS $0.197 $0.797 $0.983
Month Ago EPS $0.197 $0.797 $0.985
# Rev Up 1 1 1
# Rev Down 0 0 0
Three Months Ago EPS $0.210 $0.830 $1.057
Year/Year Chg 23.1% 32.8% 100.0%
Financials ADMA Industry
Median		 Percentile
(All Stocks)
Sales (TTM) (Mil) $512 $37 41%
Net Income (TTM) (Mil) $169 ($43) 66%
EPS (TTM) $0.718 ($1.400) 57%
Operating Cash Flow (TTM) (Mil) $137 ($31) 55%
Net Cash Flow (TTM) (Mil) $46 $2 69%
Long-Term Debt (Q1) (Mil) $199 $4 50%
Enterprise Value (Q1) (Mil) na $160 na
Valuation ADMA Industry
Median		 Percentile
(All Stocks)
P/B 5.39 2.77 80%
P/E 13.9 19.1 34%
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) 0.6 1.0 31%
Ratios ADMA Industry
Median		 Percentile
(All Stocks)
Gross Margin 64.7% 64.2% 77%
Net Margin 33.0% (75.9%) 91%
ROA 27.2% (47.3%) 98%
ROE 41.9% (55.0%) 91%
Liabilities to Assets 40.3% 29.6% 31%
F-Score 5 2 50%

Passing Stock Screens

As of 8/20/2026, from a list of 60 stock screening strategies, ADMA meetings the criteria of 1 screen:
Stock Screen
GURU STRATEGY

Fisher (Philip) Screen

Factors: Value, Growth
A perspective on the evolution of the investment philosophy of a successful money manager who learned from his mistakes. 
Performance Since Inception: 4.6%
+/- S&P 500: -2.9

Passing Stocks

ADMA Biologics, Inc. ADMA
Genmab A/S GMAB
Harmony Biosciences Holdings, Inc. HRMY
See All 3 Stocks (as of 8/20/2026)

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors